← FDA DRUG APPROVALS

FDA ANDA · ANDA090074

PANTOPRAZOLE SODIUM

Sponsor: TORRENT PHARMS

APPLICATION
ANDA090074
TYPE
ANDA
ORIGINAL APPROVAL
2011-01-19
LATEST ACTION
2023-09-27
ROUTE
ORAL
DOSAGE FORM
TABLET, DELAYED RELEASE
MARKETING STATUS
Prescription

Products

PANTOPRAZOLE SODIUMPrescription
PANTOPRAZOLE SODIUM EQ 20MG BASE · TABLET, DELAYED RELEASE · ORAL
PANTOPRAZOLE SODIUMPrescription
PANTOPRAZOLE SODIUM EQ 40MG BASE · TABLET, DELAYED RELEASE · ORAL

Approval history

2023-09-27Labeling · Supplement 28 · standardAP
2022-08-11Labeling · Supplement 26 · standardAP
2022-01-07Labeling · Supplement 24 · standardAP
2019-11-14Labeling · Supplement 18 · standardAP
2019-11-14Labeling · Supplement 16 · standardAP
2019-11-14Labeling · Supplement 22 · standardAP
2019-11-14Labeling · Supplement 19 · standardAP
2015-04-09Labeling · Supplement 12 · standardAP
2015-02-25Labeling · Supplement 10 · standardAP
2014-12-05Labeling · Supplement 11 · standardAP
2013-05-30Labeling · Supplement 8 · standardAP
2013-05-30Labeling · Supplement 6 · standardAP
2012-01-17Labeling · Supplement 4AP
2011-01-19OriginalAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →